OHSU

IRB #

IRB00010605

Title

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Principal Investigator

Matthew Taylor

Study Purpose

To establish a safe dose of the study drug (AZD5363) by gathering information on how well it is tolerated, any potential side effects it may cause, and collecting data about how your cancer responds to the drug.

Medical Condition(s)

Breast, cervical, endometrial, or ovarian cancer, or other solid tumors.

Eligibility Criteria

1. Female or male 18 years or older.
2. Malignant breast, cervical, endometrial, or ovarian cancer, or other solid tumors, with either a PIK3CA or AKT1 mutation.
3. Cannot have diabetes.
4. Other criteria also apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

AstraZeneca

Recruitment End

04/15/2016

Compensation Provided

Yes

Compensation

$45 per visit


Go Back